Pharmacovigilance in resource-limited countries

In the past 20 years, many low- and middle-income countries have created national pharmacovigilance (PV) systems and joined the WHO’s global PV network. However, very few of them have fully functional systems. Scientific evidence on the local burden of medicine-related harm and their preventability is missing. Legislation and regulatory framework as well as financial support to build sustainable PV systems are needed. Public health programs need to integrate PV to monitor new vaccines and medicines introduced through these programs. Signal analysis should focus on high-burden preventable adverse drug problems. Increased involvement of healthcare professionals from public and private sectors, pharmaceutical companies, academic institutions and the public at large is necessary to assure a safe environment for drug therapy. WHO has a major role in supporting and coordinating these developments.

[1]  F. Hunsel.  The contribution of direct patient reporting to pharmacovigilance , 2011 .

[2]  IanC K Wong,et al.  Pharmacovigilance in China: Current Situation, Successes and Challenges , 2014, Drug Safety.

[3]  A. Pariente,et al.  Prevalence and preventability of adverse drug events in a teaching hospital: a cross-sectional study. , 2009, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[4]  R. Royer,et al.  ADVERSE DRUG REACTION MONITORING: DOING IT THE FRENCH WAY , 1985, The Lancet.

[5]  H. Gyllensten,et al.  How are the Costs of Drug-Related Morbidity Measured? , 2012, Drug Safety.

[6]  S. Olsson,et al.  The Role of the WHO Programme on International Drug Monitoring in Coordinating Worldwide Drug Safety Efforts , 1998, Drug safety.

[7]  S. Pal,et al.  Targeted Spontaneous Reporting of Suspected Renal Toxicity in Patients Undergoing Highly Active Anti-Retroviral Therapy in Two Public Health Facilities in Uganda , 2015, Drug Safety.

[8]  K. Hartigan-Go.  Empowering Consumers as Contributors for Health Product Safety: Lessons from the Philippines , 2015, Drug Safety.

[9]  S. Pal,et al.  WHO Strategy for Collecting Safety Data in Public Health Programmes: Complementing Spontaneous Reporting Systems , 2013, Drug Safety.

[10]  D Bajpai,et al.  Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study , 2007, BMC clinical pharmacology.

[11]  C M Bond,et al.  Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. , 2011, Health technology assessment.

[12]  S. Pal,et al.  Specific features of medicines safety and pharmacovigilance in Africa , 2012, Therapeutic advances in drug safety.

[13]  E. Nartey,et al.  Profile of Adverse Events in Patients Receiving Treatment for Malaria in Urban Ghana: A Cohort-Event Monitoring Study , 2014, Drug Safety.

[14]  Andy Stergachis,et al.  Pharmacovigilance Activities in 55 Low- and Middle-Income Countries , 2010, Drug safety.

[15]  M. Rawlins.  Pathogenesis of adverse drug reactions , 1977 .

[16]  K. Wilbur.  Pharmacovigilance in the Middle East , 2011, Drug Safety.

[17]  M. Steinbuch,et al.  Overview and Comparison of Postmarketing Drug Safety Surveillance in Selected Developing and Well-Developed Countries , 2010 .

[18]  Max Petzold,et al.  Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions – A Meta-Analysis , 2012, PloS one.

[19]  C. Poole,et al.  Preventable Drug-Related Hospital Admissions , 2002, The Annals of pharmacotherapy.

[20]  Remedios,et al.  COMMISSION OF THE EUROPEAN COMMUNITIES , 1601 .

[21]  Janet Sultana,et al.  Clinical and economic burden of adverse drug reactions , 2013, Journal of pharmacology & pharmacotherapeutics.

[22]  Munir Pirmohamed,et al.  Pharmacovigilance in developing countries , 2007, BMJ : British Medical Journal.

[23]  L. Garrison,et al.  A Framework for Assessing the Economic Value of Pharmacovigilance in Low- and Middle-Income Countries , 2014, Drug Safety.

[24]  P. Biswas.  Pharmacovigilance in Asia , 2013, Journal of pharmacology & pharmacotherapeutics.

[25]  M. Lindquist,et al.  Teaching Pharmacovigilance: the WHO-ISoP Core Elements of a Comprehensive Modular Curriculum , 2014, Drug Safety.

[26]  H. Yahia,et al.  Members , 1947, PMLA/Publications of the Modern Language Association of America.

[27]  L. Hazell,et al.  Under-Reporting of Adverse Drug Reactions , 2006, Drug safety.

[28]  Jack McCulley.  December, 2012 , 2013, The Lancet Neurology.

[29]  A. Isah,et al.  Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study , 2013, Drug Safety.